{"pmid":32392007,"title":"[Respiratory complaints in the time of COVID-19].","text":["[Respiratory complaints in the time of COVID-19].","The current guidelines for diagnosis and treatment of primary respiratory infections are still useful during the COVID-19 epidemic.Telephone triage of patients with respiratory complaints aims to identify patients with complications or an increased risk of complications.There are no indications to test for SARS-CoV-2 virus in general practice.During this COVID-19 epidemic, protective clothing is recommended in all physical contacts with patients with respiratory complaints.There is no reason to be cautious about using NSAIDs in patients suspected of COVID-19.Amoxicillin is first choice treatment for respiratory infections during the COVID-19 epidemic; there is lack of evidence to support azithromycin as a first choice.Respiratory rate > 24 / min or saturation <92-94% indicate imminent respiratory decompensation and may be reasons for referral.","Ned Tijdschr Geneeskd","Loogman, Masja C M","de Jong, Nynke","Platteel, Tamara N","Bouma, Margriet","Verheij, Theo J M","Opstelten, Wim","32392007"],"abstract":["The current guidelines for diagnosis and treatment of primary respiratory infections are still useful during the COVID-19 epidemic.Telephone triage of patients with respiratory complaints aims to identify patients with complications or an increased risk of complications.There are no indications to test for SARS-CoV-2 virus in general practice.During this COVID-19 epidemic, protective clothing is recommended in all physical contacts with patients with respiratory complaints.There is no reason to be cautious about using NSAIDs in patients suspected of COVID-19.Amoxicillin is first choice treatment for respiratory infections during the COVID-19 epidemic; there is lack of evidence to support azithromycin as a first choice.Respiratory rate > 24 / min or saturation <92-94% indicate imminent respiratory decompensation and may be reasons for referral."],"journal":"Ned Tijdschr Geneeskd","authors":["Loogman, Masja C M","de Jong, Nynke","Platteel, Tamara N","Bouma, Margriet","Verheij, Theo J M","Opstelten, Wim"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32392007","source":"PubMed","week":"202020|May 11 - May 17","e_drugs":["Azithromycin","Amoxicillin"],"topics":["Prevention"],"weight":1,"_version_":1666528580000022528,"score":9.490897,"similar":[{"pmid":32460369,"title":"Non-steroidal anti-inflammatory drugs in management of COVID-19; a systematic review on current evidence.","text":["Non-steroidal anti-inflammatory drugs in management of COVID-19; a systematic review on current evidence.","BACKGROUND: Since there is still no definitive conclusion regarding which non-steroidal anti-inflammatory drugs (NSAIDs) are most effective and safe in viral respiratory infections, we decided to evaluate the efficacy and safety of various NSAIDs in viral respiratory infections so that we can reach a conclusion on which NSAID is best choice for COVID-19. METHODS: A search was performed in Medline (via PubMed), Embase, and CENTRAL databases until 23 March 2020. Clinical trials on application of NSAIDs in viral respiratory infections were included. RESULTS: Six clinical trials were included. No clinical trial has been performed on COVID-19, Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome infections. Studies show that ibuprofen and naproxen not only have positive effects in controlling cold symptoms but also do not cause serious side effects in rhinovirus infections. In addition, it was found that clarithromycin, naproxen and oseltamivir combination leads to decrease in mortality rate and duration of hospitalization in patients with pneumonia due to influenza. CONCLUSION: Although based on existing evidence, NSAIDs have been effective in treating respiratory infections caused by influenza and rhinovirus, since there is no clinical trial on COVID-19 and case-reports and clinical experiences are indicative of elongation of treatment duration and exacerbation of the clinical course of patients with COVID-19, it is recommended to use substitutes such as acetaminophen for controlling fever and inflammation and be cautious about using NSAIDs in management of COVID-19 patients until there are enough evidence. Naproxen may be a good choice for future clinical trials.","Int J Clin Pract","Yousefifard, Mahmoud","Zali, Alireza","Zarghi, Afshin","Madani Neishaboori, Arian","Hosseini, Mostafa","Safari, Saeed","32460369"],"abstract":["BACKGROUND: Since there is still no definitive conclusion regarding which non-steroidal anti-inflammatory drugs (NSAIDs) are most effective and safe in viral respiratory infections, we decided to evaluate the efficacy and safety of various NSAIDs in viral respiratory infections so that we can reach a conclusion on which NSAID is best choice for COVID-19. METHODS: A search was performed in Medline (via PubMed), Embase, and CENTRAL databases until 23 March 2020. Clinical trials on application of NSAIDs in viral respiratory infections were included. RESULTS: Six clinical trials were included. No clinical trial has been performed on COVID-19, Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome infections. Studies show that ibuprofen and naproxen not only have positive effects in controlling cold symptoms but also do not cause serious side effects in rhinovirus infections. In addition, it was found that clarithromycin, naproxen and oseltamivir combination leads to decrease in mortality rate and duration of hospitalization in patients with pneumonia due to influenza. CONCLUSION: Although based on existing evidence, NSAIDs have been effective in treating respiratory infections caused by influenza and rhinovirus, since there is no clinical trial on COVID-19 and case-reports and clinical experiences are indicative of elongation of treatment duration and exacerbation of the clinical course of patients with COVID-19, it is recommended to use substitutes such as acetaminophen for controlling fever and inflammation and be cautious about using NSAIDs in management of COVID-19 patients until there are enough evidence. Naproxen may be a good choice for future clinical trials."],"journal":"Int J Clin Pract","authors":["Yousefifard, Mahmoud","Zali, Alireza","Zarghi, Afshin","Madani Neishaboori, Arian","Hosseini, Mostafa","Safari, Saeed"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32460369","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/ijcp.13557","keywords":["covid-19","ibuprofen","respiratory tract infections","viruses"],"locations":["rhinovirus"],"topics":["Treatment"],"weight":1,"_version_":1667967699015172096,"score":142.58284},{"pmid":32502132,"title":"Airway management in the operating room and interventional suites in known or suspected COVID-19 adult patients: a practical review.","text":["Airway management in the operating room and interventional suites in known or suspected COVID-19 adult patients: a practical review.","Current evidence suggests that Coronavirus Disease 2019 (COVID-19) spread occurs via respiratory droplets (particles >5 microm), and possibly through aerosol. The rate of transmission remains high during airway management. This was evident during the 2003 severe acute respiratory syndrome epidemic where those who were involved in tracheal intubation had a higher risk of infection than those who were not involved (odds ratio 6.6). We describe specific airway management principles for patients with known or suspected COVID-19 disease for an array of critical care and procedural settings. We conducted a thorough search of the available literature of airway management of COVID-19 across a variety of international settings. In addition, we have analyzed various medical professional body recommendations for common procedural practices such as interventional cardiology, gastroenterology and pulmonology. A systematic process that aims to protect the operators involved via appropriate personal protective equipment, avoidance of unnecessary patient contact and minimalization of periprocedural aerosol generation are key components to successful airway management. For operating room cases requiring general anesthesia or complex interventional procedures, tracheal intubation should be the preferred option. For interventional procedures when tracheal intubation is not indicated, cautious conscious sedation appears to be a reasonable approach. Awake intubation should be avoided unless it is absolutely necessary. Extubation is a high-risk procedure for aerosol and droplet spread and needs thorough planning and preparation. As updates and modifications in the management of COVID-19 are still evolving, local guidelines, appraised at regular intervals, are vital in optimizing clinical management.","Anesth Analg","Thiruvenkatarajan, Venkatesan","Wong, David T","Kothandan, Harikrishnan","Sekhar, Vimal","Adhikary, Sanjib Das","Currie, John","Van Wijk, Roelof","32502132"],"abstract":["Current evidence suggests that Coronavirus Disease 2019 (COVID-19) spread occurs via respiratory droplets (particles >5 microm), and possibly through aerosol. The rate of transmission remains high during airway management. This was evident during the 2003 severe acute respiratory syndrome epidemic where those who were involved in tracheal intubation had a higher risk of infection than those who were not involved (odds ratio 6.6). We describe specific airway management principles for patients with known or suspected COVID-19 disease for an array of critical care and procedural settings. We conducted a thorough search of the available literature of airway management of COVID-19 across a variety of international settings. In addition, we have analyzed various medical professional body recommendations for common procedural practices such as interventional cardiology, gastroenterology and pulmonology. A systematic process that aims to protect the operators involved via appropriate personal protective equipment, avoidance of unnecessary patient contact and minimalization of periprocedural aerosol generation are key components to successful airway management. For operating room cases requiring general anesthesia or complex interventional procedures, tracheal intubation should be the preferred option. For interventional procedures when tracheal intubation is not indicated, cautious conscious sedation appears to be a reasonable approach. Awake intubation should be avoided unless it is absolutely necessary. Extubation is a high-risk procedure for aerosol and droplet spread and needs thorough planning and preparation. As updates and modifications in the management of COVID-19 are still evolving, local guidelines, appraised at regular intervals, are vital in optimizing clinical management."],"journal":"Anesth Analg","authors":["Thiruvenkatarajan, Venkatesan","Wong, David T","Kothandan, Harikrishnan","Sekhar, Vimal","Adhikary, Sanjib Das","Currie, John","Van Wijk, Roelof"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32502132","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1213/ANE.0000000000005043","topics":["Prevention"],"weight":1,"_version_":1668804508758573056,"score":122.65285},{"pmid":32396445,"title":"Approaching Otolaryngology Patients During the COVID-19 Pandemic.","text":["Approaching Otolaryngology Patients During the COVID-19 Pandemic.","Objective. To describe coronavirus disease 2019 (COVID-19) patient presentations requiring otolaryngology consultation and provide recommendations for protective measures based on the experience of ear, nose, and throat (ENT) departments in 4 Chinese hospitals during the COVID-19 pandemic. Study Design. Retrospective case series. Setting. Multicenter. Subjects and Methods. Twenty hospitalized COVID-19 patients requiring ENT consultation from 3 designated COVID-19 hospitals in Wuhan, Shanghai, and Shenzhen were identified. Data on demographics, comorbidities, COVID-19 symptoms and severity, consult reason, treatment, and personal protective equipment (PPE) use were collected and analyzed. Infection control strategies implemented for ENT outpatients and emergency room visits at the Eye and ENT Hospital of Fudan University were reported. Results. Median age was 63 years, 55% were male, and 95% were in severe or critical condition. Six tracheotomies were performed. Posttracheotomy outcomes were mixed (2 deaths, 2 patients comatose, all living patients still hospitalized). Other consults included epistaxis, pharyngitis, nasal congestion, hyposmia, rhinitis, otitis externa, dizziness, and tinnitus. At all hospitals, powered air-supply filter respirators (PAPRs) were used for tracheotomy or bleeding control. PAPR or N95-equivalent masks plus full protective clothing were used for other complaints. No inpatient ENT providers were infected. After implementation of infection control strategies for outpatient clinics, emergency visits, and surgeries, no providers were infected at the Eye and ENT Hospital of Fudan University. Conclusions and Relevance. COVID-19 patients require ENT consultation for many reasons, including tracheotomy. Otolaryngologists play an indispensable role in the treatment of COVID-19 patients but, due to their work, are at high risk of exposure. Appropriate protective strategies can prevent infection of otolaryngologists.","Otolaryngol Head Neck Surg","Cui, Chong","Yao, Qi","Zhang, Di","Zhao, Yu","Zhang, Kun","Nisenbaum, Eric","Cao, Pengyu","Zhao, Keqing","Huang, Xiaolong","Leng, Dewen","Liu, Chunhan","Li, Ning","Luo, Yan","Chen, Bing","Casiano, Roy","Weed, Donald","Sargi, Zoukaa","Telischi, Fred","Lu, Hongzhou","Denneny, James C 3rd","Shu, Yilai","Liu, Xuezhong","32396445"],"abstract":["Objective. To describe coronavirus disease 2019 (COVID-19) patient presentations requiring otolaryngology consultation and provide recommendations for protective measures based on the experience of ear, nose, and throat (ENT) departments in 4 Chinese hospitals during the COVID-19 pandemic. Study Design. Retrospective case series. Setting. Multicenter. Subjects and Methods. Twenty hospitalized COVID-19 patients requiring ENT consultation from 3 designated COVID-19 hospitals in Wuhan, Shanghai, and Shenzhen were identified. Data on demographics, comorbidities, COVID-19 symptoms and severity, consult reason, treatment, and personal protective equipment (PPE) use were collected and analyzed. Infection control strategies implemented for ENT outpatients and emergency room visits at the Eye and ENT Hospital of Fudan University were reported. Results. Median age was 63 years, 55% were male, and 95% were in severe or critical condition. Six tracheotomies were performed. Posttracheotomy outcomes were mixed (2 deaths, 2 patients comatose, all living patients still hospitalized). Other consults included epistaxis, pharyngitis, nasal congestion, hyposmia, rhinitis, otitis externa, dizziness, and tinnitus. At all hospitals, powered air-supply filter respirators (PAPRs) were used for tracheotomy or bleeding control. PAPR or N95-equivalent masks plus full protective clothing were used for other complaints. No inpatient ENT providers were infected. After implementation of infection control strategies for outpatient clinics, emergency visits, and surgeries, no providers were infected at the Eye and ENT Hospital of Fudan University. Conclusions and Relevance. COVID-19 patients require ENT consultation for many reasons, including tracheotomy. Otolaryngologists play an indispensable role in the treatment of COVID-19 patients but, due to their work, are at high risk of exposure. Appropriate protective strategies can prevent infection of otolaryngologists."],"journal":"Otolaryngol Head Neck Surg","authors":["Cui, Chong","Yao, Qi","Zhang, Di","Zhao, Yu","Zhang, Kun","Nisenbaum, Eric","Cao, Pengyu","Zhao, Keqing","Huang, Xiaolong","Leng, Dewen","Liu, Chunhan","Li, Ning","Luo, Yan","Chen, Bing","Casiano, Roy","Weed, Donald","Sargi, Zoukaa","Telischi, Fred","Lu, Hongzhou","Denneny, James C 3rd","Shu, Yilai","Liu, Xuezhong"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32396445","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1177/0194599820926144","keywords":["covid-19","sars-cov-2","health care worker (hcw)","infection control measures","personal protective equipment (ppe)","preexamination","tracheotomy"],"locations":["Chinese","Wuhan","Shanghai","Shenzhen","Otolaryngologists"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1666627827921846272,"score":113.154076},{"pmid":32409150,"title":"An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic.","text":["An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic.","BACKGROUND: Chloroquine or hydroxychloroquine (chloroquine) plus azithromycin is considered as therapy for COVID-19. With benefit evaluations underway, safety concerns due to potential additive effects on QTc prolongation should be addressed. OBJECTIVE: We compared risk of cardiac adverse events between combinations of chloroquine and azithromycin and chloroquine and amoxicillin. METHODS: We conducted a retrospective cohort study using the IBM MarketScan Commercial Claims and Medicare Supplemental Databases, 2005-2018. We included autoimmune disease patients aged >/=18 years initiating azithromycin or amoxicillin for >/=5 days during chloroquine treatment. Patients had continuous insurance coverage >/=6 months before combination use until 5 days thereafter or inpatient death. Two outcomes were sudden cardiac arrest/ventricular arrhythmias (SCA/VA) and cardiac symptoms. We followed patients for up to 5 days to estimate hazard ratios (HR). Covariates were adjusted using stabilized inverse probability treatment weighting. RESULTS: We identified two SVC/VA events among >145,000 combination users. The adjusted incidence of cardiac symptoms among azithromycin and amoxicillin users was 276 vs 254 per 10,000 person-years with an adjusted HR of 1.10 (95%CI, 0.62-1.95). CONCLUSION: Combination use of chloroquine and azithromycin at routine doses did not show pronounced increases in arrhythmias in this real-world population, though small sample size and outcome rates limit conclusions.","Res Social Adm Pharm","Vouri, Scott M","Thai, Thuy N","Winterstein, Almut G","32409150"],"abstract":["BACKGROUND: Chloroquine or hydroxychloroquine (chloroquine) plus azithromycin is considered as therapy for COVID-19. With benefit evaluations underway, safety concerns due to potential additive effects on QTc prolongation should be addressed. OBJECTIVE: We compared risk of cardiac adverse events between combinations of chloroquine and azithromycin and chloroquine and amoxicillin. METHODS: We conducted a retrospective cohort study using the IBM MarketScan Commercial Claims and Medicare Supplemental Databases, 2005-2018. We included autoimmune disease patients aged >/=18 years initiating azithromycin or amoxicillin for >/=5 days during chloroquine treatment. Patients had continuous insurance coverage >/=6 months before combination use until 5 days thereafter or inpatient death. Two outcomes were sudden cardiac arrest/ventricular arrhythmias (SCA/VA) and cardiac symptoms. We followed patients for up to 5 days to estimate hazard ratios (HR). Covariates were adjusted using stabilized inverse probability treatment weighting. RESULTS: We identified two SVC/VA events among >145,000 combination users. The adjusted incidence of cardiac symptoms among azithromycin and amoxicillin users was 276 vs 254 per 10,000 person-years with an adjusted HR of 1.10 (95%CI, 0.62-1.95). CONCLUSION: Combination use of chloroquine and azithromycin at routine doses did not show pronounced increases in arrhythmias in this real-world population, though small sample size and outcome rates limit conclusions."],"journal":"Res Social Adm Pharm","authors":["Vouri, Scott M","Thai, Thuy N","Winterstein, Almut G"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32409150","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.sapharm.2020.04.031","keywords":["covid19","cardiac events","chloroquine","hydroxychloroquine","qtc prolongation"],"locations":["amoxicillin"],"e_drugs":["Chloroquine","Amoxicillin","Hydroxychloroquine","Azithromycin"],"topics":["Treatment"],"weight":1,"_version_":1666897319263469568,"score":107.46291},{"pmid":32418728,"title":"Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection.","text":["Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection.","Non-steroidal anti-inflammatory drugs (NSAIDs) have an optional prescription status that has resulted in frequent use, in particular for the symptomatic treatment of fever and non-rheumatic pain. In 2019, a multi-source analysis of complementary pharmacological data showed that using NSAIDs in these indications (potentially indicative of an underlying infection) increases the risk of a severe bacterial complication, in particular in the case of lung infections. First, the clinical observations of the French Pharmacovigilance Network showed that severe bacterial infections can occur even after a short NSAID treatment, and even if the NSAID is associated with an antibiotic. Second, pharmacoepidemiological studies, some of which minimized the protopathic bias, all converged and confirmed the risk. Third, experimental in vitro and in vivo animal studies suggest several biological mechanisms, which strengthens a causal link beyond the well-known risk of delaying the care of the infection (immunomodulatory effects, effects on Streptococcus pyogenes infections, and reduced antibiotics efficacy). Therefore, in case of infection, symptomatic treatment with NSAIDs for non-severe symptoms (fever, pain, or myalgia) is not to be recommended, given a range of clinical and scientific arguments supporting an increased risk of severe bacterial complication. Besides, the existence of a safer drug alternative, with paracetamol at recommended doses, makes this recommendation of precaution and common sense even more legitimate. In 2020, such recommendation is more topical than ever with the emergence of COVID-19, especially since it results in fever, headaches, muscular pain, and cough, and is further complicated with pneumopathy, and given experimental data suggesting a link between ibuprofen and the level of expression of angiotensin-converting enzyme 2.","Therapie","Micallef, Joelle","Soeiro, Thomas","Jonville-Bera, Annie-Pierre","32418728"],"abstract":["Non-steroidal anti-inflammatory drugs (NSAIDs) have an optional prescription status that has resulted in frequent use, in particular for the symptomatic treatment of fever and non-rheumatic pain. In 2019, a multi-source analysis of complementary pharmacological data showed that using NSAIDs in these indications (potentially indicative of an underlying infection) increases the risk of a severe bacterial complication, in particular in the case of lung infections. First, the clinical observations of the French Pharmacovigilance Network showed that severe bacterial infections can occur even after a short NSAID treatment, and even if the NSAID is associated with an antibiotic. Second, pharmacoepidemiological studies, some of which minimized the protopathic bias, all converged and confirmed the risk. Third, experimental in vitro and in vivo animal studies suggest several biological mechanisms, which strengthens a causal link beyond the well-known risk of delaying the care of the infection (immunomodulatory effects, effects on Streptococcus pyogenes infections, and reduced antibiotics efficacy). Therefore, in case of infection, symptomatic treatment with NSAIDs for non-severe symptoms (fever, pain, or myalgia) is not to be recommended, given a range of clinical and scientific arguments supporting an increased risk of severe bacterial complication. Besides, the existence of a safer drug alternative, with paracetamol at recommended doses, makes this recommendation of precaution and common sense even more legitimate. In 2020, such recommendation is more topical than ever with the emergence of COVID-19, especially since it results in fever, headaches, muscular pain, and cough, and is further complicated with pneumopathy, and given experimental data suggesting a link between ibuprofen and the level of expression of angiotensin-converting enzyme 2."],"journal":"Therapie","authors":["Micallef, Joelle","Soeiro, Thomas","Jonville-Bera, Annie-Pierre"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32418728","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.therap.2020.05.003","keywords":["anti-inflammatory agents","covid-19","infections","non-steroidal","pharmacoepidemiology","pharmacovigilance","respiratory tract infections","superinfection"],"e_drugs":["Acetaminophen","Ibuprofen"],"topics":["Treatment"],"weight":1,"_version_":1667159284580876288,"score":102.89688}]}